What saves lives is not the exam alone, but proper care afterward
Brazil has taken a quiet but consequential step in its long struggle against cancer: the public health system will now offer a simple, home-based stool test to more than 40 million asymptomatic citizens between 50 and 75, in hopes of catching colorectal cancer — the country's second most common — before it announces itself through suffering. Announced in Lyon by Health Minister Alexandre Padilha on May 21st, the adoption of the FIT immunochemical test into the SUS marks a pragmatic reckoning with a disease that claims nearly 54,000 new Brazilian lives each year. The test itself is modest in form but ambitious in reach; what it demands of the system that receives its results is another matter entirely.
- Colorectal cancer silently affects 53,800 Brazilians annually, and the vast majority of those at risk have never been screened — a gap the new FIT protocol is designed to close.
- The test is disarmingly simple: a home stool sample, a swab, a tube sent to a lab — no colonoscopy, no sedation, no lost workday — lowering the barrier to screening for millions.
- Yet the test carries inherent uncertainty: a positive result may reflect hemorrhoids rather than cancer, while a negative result cannot guarantee a clean bill of health, since some lesions bleed intermittently.
- The real pressure now falls on the SUS infrastructure — a system already stretched thin must be ready to deliver timely colonoscopies and treatment for the wave of positive results the new protocol will generate.
- Specialists are clear: early detection saves lives only when the care that follows is swift and accessible — the exam is the beginning of the story, not its resolution.
Brazil's Health Ministry announced on May 21st, during an official visit to Lyon, France, that the SUS will begin deploying the FIT test — a stool-based immunochemical screening tool — to asymptomatic men and women between 50 and 75 years old. The move targets a population of more than 40 million Brazilians and confronts a disease that ranks as the country's second most common cancer, with roughly 53,800 new cases expected annually through 2028.
The FIT test works by detecting microscopic traces of blood in stool samples using specific antibodies, offering greater diagnostic accuracy than older methods. The process is designed for accessibility: patients collect a small sample at home with a provided swab, place it in a tube, and send it to a laboratory. No colonoscopy, no sedation, no disruption to daily life.
Still, the test is not a verdict. A positive result can stem from benign conditions like hemorrhoids or intestinal inflammation, while a negative result offers no absolute certainty — some lesions simply do not bleed at the moment of collection. International guidelines recommend repeating the screening every one to two years, adjusted for age and family history.
Specialists are careful to frame the test as a beginning, not an end. Finding disease before symptoms appear dramatically improves survival and treatment options — but only if what follows is equally accessible. A positive FIT result requires colonoscopy confirmation, and any delay in follow-up care can undo the gains of early detection entirely.
This is the strategy's central vulnerability. The SUS will need to absorb a significant increase in demand for colonoscopies, surgical referrals, and treatment — infrastructure that remains uneven across Brazil's regions. The protocol also clarifies its limits: those already showing warning signs such as rectal bleeding, unexplained weight loss, or persistent bowel changes should seek care immediately, regardless of age. Whether the promise of early detection is fulfilled depends not on the test itself, but on the system's capacity to act on what it finds.
Brazil's Health Ministry announced a shift in how the country screens for colorectal cancer. Starting immediately, the public health system will deploy the FIT test—a simple stool-based screening tool—to reach millions of Brazilians who have never been tested. The announcement came from Health Minister Alexandre Padilha during an official visit to Lyon, France, on Wednesday, May 21st.
The new protocol targets asymptomatic men and women between 50 and 75 years old, a population that encompasses more than 40 million Brazilians. Colorectal cancer ranks as the second most common cancer in the country, excluding non-melanoma skin tumors. The National Cancer Institute estimates roughly 53,800 new cases will be diagnosed annually through 2028. For a public health system already stretched thin, the decision to adopt a less invasive screening method represents a pragmatic attempt to catch the disease before it becomes symptomatic and harder to treat.
The FIT test works by detecting microscopic traces of blood in stool samples—blood invisible to the naked eye that might signal the presence of polyps, precancerous lesions, or cancer itself. Unlike older screening methods, the test uses specific antibodies to identify human blood, which increases diagnostic accuracy. The procedure is straightforward: a patient receives a collection kit, takes a small sample at home using a provided swab, places it in a tube, and sends it to a laboratory. No colonoscopy required at this stage. No sedation. No time off work.
But the test is not a definitive answer. A positive result does not automatically mean cancer. Benign conditions—hemorrhoids, intestinal inflammation—can also produce bleeding that the FIT detects. Conversely, a negative result offers no absolute guarantee. Some lesions do not bleed at the moment of collection, meaning they slip past the test. This is why international guidelines recommend repeating screening every one or two years, depending on age and family history.
Specialists emphasize that early detection is the real prize. Finding disease before symptoms appear dramatically improves survival rates and treatment options. Yet they also warn that the test itself is only half the equation. A positive FIT result means nothing if the patient cannot access a colonoscopy to confirm the finding, or if treatment is delayed or unavailable. One expert noted plainly: what saves lives is not the exam alone, but proper care of the patient when further investigation becomes necessary.
This is where the strategy faces its greatest test. The SUS—Brazil's unified public health system—will need to absorb a surge in positive results and ensure rapid access to colonoscopy, surgery, and appropriate treatment. The infrastructure to handle this volume does not yet exist in many regions. Delays in follow-up care can erase the benefits of early detection.
The protocol applies to people without symptoms between 50 and 75. Those showing warning signs—blood in stool, unexplained weight loss, anemia, persistent bowel changes, abdominal pain—should seek medical attention regardless of age. Patients with a family history of colorectal cancer, genetic syndromes, or inflammatory bowel disease may need to begin screening earlier, based on individual medical judgment.
The rollout represents an acknowledgment that Brazil's cancer burden is growing and that the current system cannot afford to wait for symptoms to appear. Whether the health system can deliver on the promise of early detection depends not on the test itself, but on what happens after the result comes back.
Notable Quotes
What reduces mortality is not just the exam, but caring correctly for the patient when further investigation is needed, with rapid access to colonoscopy, surgery, and appropriate treatment.— Health specialist cited in announcement
The Hearth Conversation Another angle on the story
Why does Brazil need a new screening test now? Wasn't colorectal cancer already being detected?
It was, but only in people who could afford private care or who showed up at the hospital already sick. The FIT test is cheap and simple enough to deploy across the public system. The ministry is betting they can catch cases before symptoms appear, when treatment is far more effective.
So the test is foolproof?
No. It misses some cancers and flags some benign bleeding. The real work happens after the result comes back—that's where most systems fail. You need colonoscopy capacity, surgical capacity, oncology capacity. Brazil doesn't have enough of any of those yet.
What happens to someone who tests positive?
They need a colonoscopy to see what's actually there. If it's a polyp, it gets removed. If it's cancer, they need surgery or chemotherapy. The problem is wait times. In many parts of Brazil, that colonoscopy might take months.
Is this test better than colonoscopy?
Different. Colonoscopy is the gold standard—it can find and remove polyps in one procedure. But it's expensive, invasive, and requires trained specialists. FIT is a filter. It identifies who needs the colonoscopy. If you screen 40 million people with colonoscopy, the system collapses. With FIT, you screen 40 million and refer maybe 5 to 10 percent for colonoscopy.
Who benefits most from this?
People in their 50s and 60s without symptoms who would never have been screened otherwise. In Brazil, that's tens of millions. But the benefit only materializes if they can actually get the follow-up care.
What's the biggest risk?
Creating a backlog of people with positive tests waiting months for colonoscopy. You've identified disease early, but you haven't treated it. That's worse than not screening at all.